Jonathan graduated in 2020 from Rowan University, obtaining his B.S. in biochemistry. During his undergraduate research, Jonathan worked under Dr. James Grinias, developing low-cost droplet microfluidic devices for applications in biomedical analysis. During the summer of 2018, he worked as an NSF REU recipient at the University of Utah under Dr. Jon Rainier working on synthesizing virulence inhibitors as novel antibiotics, derived from the natural product Discorhabdin Z. In the Fall of 2020, he joined Dr. David Sarlah’s group at UIUC, working on total synthesis and medicinal chemistry. In this time, he has published multiple articles related to various cannabinoid oxidative metabolites and completed a total synthesis of darobactin A. In the spring of 2024, Jonathan joined the Hergenrother group to pursue the development of novel fabimycin derivatives.